Healthcare Companies in the News for July 8 - Alliqua, Inc., Derma Sciences, MiMedx, Integra LifeSciences, Oculus Innovative
CORAL SPRINGS, Florida, July 8, 2013 /PRNewswire/ --
FinancialNewsMedia.com issues market news updates for today's active healthcare companies: Alliqua, Inc. (OTCQB: ALQA), Derma Sciences Inc. (NASDAQ: DSCI), MiMedx Group, Inc. (NASDAQ: MDXG), Integra LifeSciences Holdings Corporation (NASDAQ: IART) and Oculus Innovative Sciences, Inc. (NASDAQ: OCLS)
Headline News Alert: Alliqua, Inc. (OTCQB:ALQA) today announced that it has successfully met its financing goals, raising $3 million through the sale of common stock and warrants over the past 3 months. A group of accredited investors purchased the equity at $0.081 per share, coupled with a warrant to purchase an additional share of common stock at $0.097 per share. The first $1 million investment, as previously disclosed by the Company, took place between April and May of 2013. The remaining $2 million was raised on June 28, 2013 and was led by group of Alliqua's management and board of directors, including Jerome Zeldis, Dave Johnson, David Stefansky, Joseph Leone and Kenneth Pearsen. Dr. Zeldis, who serves as the Chairman of the Board of Alliqua, is the current chief medical officer of Celgene Corporation. To read the entire press release, please go to http://finance.yahoo.com/q/h?s=ALQA+Headlines
Derma Sciences Inc. (NASDAQ: DSCI) closed up slightly on Friday July 5th in light trading. DSCI operates as a medical technology company primarily in the United States and Canada. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. The company offers Medihoney dressings for the management of non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; TCC-EZ dressing system for the management of diabetic foot ulcers; and Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings.
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced recently that it has been included in the Russell 2000, the Russell 3000 and the Russell Global Indexes effective at the start of trading on July 1, 2013. Its biomaterial platform technologies include HydroFix and CollaFix device technologies; and AmnioFix and EpiFix tissue technologies. Its tissue technologies, processed from the human amniotic membrane, utilize its proprietary Purion process to produce minimally manipulated implants. MDXG closed up slightly on Friday on below average trading volume.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) recently announced the company will release its second quarter 2013 financial results on Thursday, August 1, 2013. The company has scheduled a conference call for 8:30 AM ET the same day to discuss the results. Integra's senior management team will host the conference call, which will be open to all listeners. For complete details, please visit http://www.integralife.com. There will also be a question and answer session following the prepared remarks. IART develops, manufactures, and markets surgical implants and medical instruments for neurosurgery, extremity reconstruction, orthopedics, and general surgery.
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 27 countries, announced the allowance of a Mexican patent for the use of the company's novel antimicrobial surgical solution in the treatment and prevention of peritonitis. The imminent issuance of this Mexican patent, expiring in 2027, provides Oculus' Latin American partner, More Pharma, the opportunity to pursue a new drug candidate in Latin America in parallel to Oculus' subsidiary, Ruthigen, Inc.'s, development of the drug for the U.S. market. The novel new formulation, RUT58-60, is an advanced next-generation Microcyn Technology drug candidate specifically engineered for use in invasive surgical procedures, including peritonitis.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group LLC